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Candida species are among the most common bloodstream pathogens in the United States, where the emergence
of azole-resistant Candida glabrata and Candida krusei are major concerns. Recent comprehensive longitudinal
data from Europe are lacking. We conducted a nationwide survey of candidemia during 1991–2000 in 17
university and university-affiliated hospitals representing 79% of all tertiary care hospital beds in Switzerland.
The number of transplantations and bloodstream infections increased significantly ( ). A total of 1137P ! .001
episodes of candidemia were observed: Candida species ranked seventh among etiologic agents (2.9% of all
bloodstream isolates). The incidence of candidemia was stable over a 10-year period. C. albicans remained
the predominant Candida species recovered (66%), followed by C. glabrata (15%). Candida tropicalis emerged
(9%), the incidence of Candida parapsilosis decreased (1%), and recovery of C. krusei remained rare (2%).
Fluconazole consumption increased significantly ( ). Despite increasing high-risk activities, the incidenceP ! .001
of candidemia remained unchanged, and no shift to resistant species occurred.
Candida species are the most important causes of nos-
ocomial fungal infection, a major challenge of modern
medicine. Paradoxically, medical progress associated
with an ever-growing number of invasive procedures,
increasingly aggressive immunosuppressive treatments,
and widespread use of broad-spectrum antibiotics is
the main contributor to this occurrence. Candidemia
is associated with high morbidity, prolonged hospital
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stay, high attributable mortality (∼40%), and substan-
tial health care costs [1–4].
The epidemiology of candidemia has been extensively
studied in the United States. Secular trends among hos-
pitals reporting to the National Nosocomial Infections
Surveillance (NNIS) system showed a clear-cut associa-
tion between the incidence of candidemia and the num-
ber of hospital beds and/or academic affiliation [5]. Can-
dida species were the fourth most commonly isolated
pathogens in patients with bloodstream infections and
accounted for 10% of all such infections in the 1990s
[4, 6, 7]. An inverse trend in the late 1990s among
patients in intensive care units (ICUs) was reported by
Trick et al. [8]. Although Candida albicans has been the
predominant species for several decades, a substantial
shift to dose-dependent azole-susceptible or even in-
trinsically azole-resistant non-albicans species of Can-
dida, such as Candida glabrata and Candida krusei, was
observed more recently in many US hospitals [9, 10].
Infections due to these non-albicans species are causes
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of increased morbidity and mortality [11]. Several studies have
attributed these epidemiologic changes to the increased use of
azole prophylaxis, but this remains a subject of debate [12].
Few comprehensive epidemiological data are available from
European hospitals [13, 14]. Dutch investigators reported a 2-
fold increase in the incidence of candidemia, with a shift toward
non-albicans species of Candida in university hospitals in the
early 1990s [13]. In contrast, a Norwegian survey conducted
during the same period described a stable incidence of can-
didemia and a stable distribution of Candida species [15]. A
study from the Invasive Fungal Infections Group of the Eu-
ropean Organization for the Research and Treatment of Cancer
reported that C. glabrata and C. krusei were recovered from
higher proportions of patients with cancer who received azole
prophylaxis than from those who did not [11]. A laboratory-
based investigation conducted by the European Confederation
of Clinical Mycology (ECCM) in 1998–1999 showed the pre-
dominance of C. albicans.
These observations suggest that the epidemiology of candi-
demia in Europe might differ from that in the United States.
However, to our knowledge, no recent longitudinal multicenter
study has been performed in Europe. We conducted a nationwide
survey of Swiss tertiary care hospitals to study the secular trends
in patient-care activities and hospital characteristics associated
with the epidemiology of candidemia during 1991–2000.
METHODS
Participating hospitals. All Swiss university hospitals (5
health care centers and 2 independent pediatric hospitals) and
a representative sample of university-affiliated tertiary care
teaching centers ( ) were included in a retrospective sur-np 11
vey. These institutions are distributed across the country and
play a key role in the national health care system by serving
the majority of the population of Switzerland (∼6,100,000
[84%] of 7,200,000 residents). All hematopoietic stem cell and
solid-organ transplantations are performed in these centers,
where infectious diseases specialists are in charge of prevention,
control, and management of infections.
Study variables. The following variables were recorded by
questionnaire survey: hospital characteristics in 2000 (type of
hospital; number of beds; number of patient admissions; and
patient-days spent in the medical, surgical, and pediatric wards
and ICUs); high-risk activities for invasive fungal infection in
2000 (the number of cases of acute leukemia and hematopoietic
stem cell and solid-organ transplantations); clinical and/or
teaching activities and resources associated with the manage-
ment of infectious diseases and infection-control programs in
2000; laboratory methods used for the diagnosis of candidemia
(see below); episodes of candidemia during 1991–2000 (num-
ber of isolates of each species; number of isolates tested and
found to be resistant to fluconazole, amphotericin B, or 5-
flucytosine; and patient location in the hospital at the time of
candidemia). The questionnaire was distributed to reference
infectious diseases specialist(s) and clinical microbiologist(s) at
each participating hospital. Returned questionnaires (from 17
of the 18 hospitals) were checked by the survey coordinators
for completeness and consistency. Those with missing data or
inconsistencies were returned for completion and/or correction.
Data on the number of patient-days spent in the hospital,
the transplantation activities, the number of blood cultures
performed, the 10 most frequently recovered bloodstream iso-
lates, and the consumption of fluconazole during 1991–2000
were additionally obtained from a representative sample of uni-
versity and university-affiliated hospitals. General data on the
characteristics of Swiss hospitals were obtained from the Swiss
Federal Office for Statistics (http://www.statistique.admin.ch).
Participating microbiology laboratories. Sixteen micro-
biology laboratories are affiliated with the 17 participating hos-
pitals. All laboratories used automated blood culture systems
(12 used Bactec [Becton Dickinson] and 5 used BacT/Alert
[bioMe´rieux]), and 7 (44%) of 16 used special blood culture
bottles for fungus detection (5 used Bactec Mycosis IC/F vials
[Becton Dickinson] and 2 used other types). Recognized stan-
dard laboratory techniques for Candida species identification
were used by all laboratories [16]. Identification of Candida
bloodstream isolates was systematically performed by 12 (75%)
of 16 laboratories; 3 (19%) of 16 laboratories submitted strains
for identification to a referral laboratory. Antifungal suscepti-
bility testing, the quality control of which was based on NCCLS
recommendations, was performed in 7 (44%) of 16 laboratories
[17]. In 2000, 8 (50%) of 16 institutions sent selected strains
to a referral laboratory for antifungal susceptibility testing.
Statistical analysis. Continuous variables were compared
using Student’s t test or the Mann-Whitney U test, as appro-
priate. Proportions were compared using the x2 test or Fisher’s
exact test, as appropriate. Linear trends over time were analyzed
by nonparametric Spearman rank order correlation analysis,
using years as the independent variable. All P values were based
on 2-tailed tests of significance ( ). Statistical analysis wasP ! .05
performed using SPSS software, version 11.0 (SPSS).
RESULTS
Hospital characteristics and patient-care activities. The
number of beds, administrative data, and high-risk patient-care
activities of the 17 participating institutions in 2000 are sum-
marized in table 1. A total of 9333 beds representing 79% of
all tertiary care hospital beds in Switzerland were included in
the survey; 56% of the beds were in 7 university hospitals, and
44% were in 10 university-affiliated institutions. The median
number of beds was higher among university hospitals (977
Candidemia Trends, Switzerland 1991–2000 • CID 2004:38 (1 February) • 313
Table 1. Characteristics and activities of 17 surveyed Swiss tertiary care hospitals, 2000.
Characteristic
Hospital type
University University affiliated All
Hospital size, no. of bedsa
100–249 beds 2 (117–120)b 3 (209–242) 5 (117–242)
250–499 beds … 3 (250–402) 3 (250–402)
500–749 beds … 4 (502–704) 4 (502–704)
750–1000 beds 3 (855–977) … 3 (855–977)
11000 beds 2 (1022–1200) … 2 (1022–1200)
Total no. of bedsc 5186 4147 9333
No. of patient admissionsc 196,006 (5400–44,599) 142,060 (8534–24,506) 338,066 (5400–44,599)
Patient-days, by wardc
Medicine 469,668 (55,026–136,985) 422,440 (21,333–64,986) 892,118 (21,333–136,985)
Surgery 456,776 (74,499–110,282) 427,171 (15,890–81,940) 883,947 (15,890–110,282)
Pediatrics 163,903 (17,283–49,644)d 81,081 (2645–25,852) 244,984 (2645–49,644)
ICU 93,798 (8150–20,511)d 47,318 (1741–9177) 141,116 (1741–20,511)
Total 1,184,155 (44,150–316,749) 978,010 (43,769–181,795) 2,162,165 (43,769–316,749)
Occupancy rate, median % (range) 86 (74–96) 85 (72–93) 85.5 (72–96)
Acute leukemia, no. of patients 179e 73 252
Type of transplantation, no. performed
Solid organ 400e,f 21g 421
Allogeneic HSC 110e … 110
Autologous HSC 215e 44 259
Total 725e 65 790
NOTE. HSC, hematopoietic stem cell; ICU, intensive care unit.
a Data are no. of hospitals (range of no. of beds for individual hospitals).
b Both are independent pediatric university hospitals.
c Data are total values for all surveyed hospitals.
d for proportions of pediatric and ICU patient-days over total patient-days in university versus university-affiliated hospitals.P ! .001
e for university vs. university-affiliated hospitals.P ! .001
f Includes kidney (248 transplantations), liver (77), heart (38), lung-heart (24), and pancreas (13).
g All were kidney transplantations.
beds [range, 855–1200 beds], not including the 2 independent
pediatric hospitals) than among university-affiliated hospitals
(380 beds; range, 209–704 beds; ). In 2000, 338,066 ad-P ! .05
missions and 2,162,165 patient-days were reported by the par-
ticipating institutions. Significantly more patient-days were re-
ported by university hospitals than by university-affiliated
hospitals ( ). ICUs accounted for 7.9% of patient-daysP ! .05
in university hospitals, compared with 4.8% of patient-days in
university-affiliated institutions ( ).P ! .001
All surveyed hospitals had clinical and teaching activities
associated with infectious diseases. All university hospitals—
with the exception of 1 independent pediatric center—and 6
(60%) of 10 university-affiliated hospitals had an infection-
control program (85% used the Centers for Disease Control
and Prevention definitions for nosocomial infections).
In 2000, most cases of acute leukemia (71%) and transplan-
tations (92%) were reported by university hospitals. In 3 uni-
versity hospitals, hematopoietic stem cell transplantations in-
creased 124%, from 55 in 1992 to 123 in 2000 ( ;rp 0.83 P !
), and solid-organ transplantations increased 95% during the.005
same period, from 108 to 211 ( ; ) (figure 1A).rp 0.95 P ! .001
Patient location in the hospital and the incidence of can-
didemia. Data on the hospital ward distribution of 92 (77%)
of all 117 patients with candidemia reported in 2000 were avail-
able from 10 hospitals. The overall incidence of infection was
0.49 cases per 10,000 patient-days. When university (np5) and
university-affiliated hospitals ( ) were compared, the inci-np 5
dence of candidemia was higher in the former, but the difference
did not reach statistical significance ( ). The incidence ofPp .17
candidemia varied according to patient location in the hospital
(table 2). Overall, candidemia occurred 7 times more frequently
in ICUs than in other wards ( ). This difference reachedPp .11
statistical significance in university hospitals ( ).P ! .01
Information from 3 university hospitals and 2 university-
affiliated hospitals on patient location in the hospital at the
time of candidemia was available for 664 episodes during 1991–
2000 (figure 2). A comparison of the periods 1991–1995 and
1996–2000 showed that 109 (32%) of 355 and 107 (35%) of
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Figure 1. A, Transplantation activity in 3 university hospitals during 1991–2000. The increase over time is statistically significant for hematopoietic
stem cell transplantations ( ; ) and solid-organ transplantations ( ; ). B, Blood cultures performed in 3 university andrp 0.83 P ! .005 rp 0.95 P ! .001
3 university-affiliated hospitals during 1991–2000. The total number of blood cultures per 10,000 patient-days per year increased significantly (rp
in university hospitals [ ] and in university-affiliated hospitals [ ]). Similar trends were observed for the number of positive1.0 P ! .001 rp 0.95 P ! .001
blood culture results (i.e., growth of any pathogen) ( in university hospitals [ ] and in university-affiliated hospitals [rp 0.81 P ! .001 rp 0.90 P !
]). C, Incidence of candidemia in 3 university and 3 university-affiliated hospitals during 1991–2000. No significant trend was found during the.001
10-year period. However, during 1991–1996, the incidence increased significantly ( ; ) in university-affiliated hospitals.rp 0.90 P ! .05
309 of all episodes, respectively, occurred in patients in ICUs.
The proportion of isolates recovered from patients in medical
wards (including hemato-oncology units) and medical ICUs
increased from 25% to 31% ( ) and from 10% to 15%Pp .06
( ), respectively. In contrast, the proportion of isolatesPp .06
recovered from patients in pediatric wards decreased from 22
(6%) of 355 to 6 (2%) of 309 ( ). The proportions ofP ! .01
Candida isolates recovered from patients in other hospital sec-
tors did not significantly differ over time. No significant dif-
ference was observed between university and university-affili-
ated institutions.
Candidemia trends during 1991–2000. Data on the num-
ber of positive blood culture results and the incidence of can-
didemia during 1991–2000 were available for 3 university hos-
pitals and 3 university-affiliated hospitals. In these institutions,
533,490 blood cultures were performed over a 10-year period.
Of these, 52,565 (9.8%) were positive (i.e., cultures yielded any
pathogen). As shown in figure 1B, the total number of blood
cultures performed per 10,000 patient-days increased from 304
in 1991 to 479 in 2000 in university hospitals ( ;rp 1.0 P !
) and from 186 to 299 during the same period in university-.001
affiliated hospitals ( ; ). Similar trends were ob-rp 0.95 P ! .001
served for the annual number of positive blood culture results
(i.e., cultures yielded any pathogen), which increased from 27
to 43 ( ; ) and 29 to 41 positive blood culturerp 0.81 P ! .001
results per 10,000 patient-days ( ; ), respectivelyrp 0.90 P ! .001
(figure 1B).
In the surveyed hospitals, Candida species accounted for
2.9% of the bloodstream pathogens (median annual propor-
tion, 2.8%; range, 2.3%–3.4%) and ranked seventh (median
annual rank, eighth; range, sixth to ninth) behind coagulase-
negative staphylococci (20.2%), Escherichia coli (19.4%), Staph-
ylococcus aureus (12.7%), Streptococcus pneumoniae (6.7%),
other streptococci (4.7%), and Klebsiella species (3.9%) and
ahead of enterococci (2.6%), Pseudomonas aeruginosa (2.6%),
and anaerobes (1.4%). No significant difference was observed
between university and university-affiliated hospitals.
These 6 centers reported 774 (68%) of all 1137 episodes of
candidemia recorded in the survey over 10 years. The median
incidence of candidemia was 0.50 episodes per 10,000 patient-
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Table 2. Data on the number of episodes and the incidences of candidemia in 2000, according to patient
location in the hospital, reported by 17 surveyed Swiss tertiary care hospitals.
Patient
location
Hospital type
University University affiliated All
No. of
episodes Incidencea
No. of
episodes Incidencea
No. of
episodes Incidencea
Ward 45 0.47 (0.16–0.64) b 13 0.16 (0.06–0.57) 58 0.33 (0.06–0.64) c
Medicald 25 0.51 (0.25–1.19)e,f 5 0.15 (0–0.47) 30 0.39 (0–1.19)
Surgical 14 0.23 (0.09–0.64)g 6 0 (0–1.03) 20 0.27 (0–1.03)
Pediatric 0 0 0 0 0 0
ICU 23 1.9 (0.91–6.7) 7 0 (0–9.36) 30 2.36 (0–9.36)
Medical 9 2.5 (1.67–13.3)h 3 0 (0–12.3) 12 3.33 (0–13.3)
Surgical 13 2.86 (0–12) 4 0 (0–12.5) 17 3.27 (0–12.5)
Pediatrici 1 0 (0–0.5) 0 0 1 0.26 (0–0.5)
Overall 70j 0.57 (0.44–1.04)k 22j 0.35 (0.06–1.14) 92l 0.49 (0.06–1.14)
NOTE. ICU, intensive care unit.
a Data are median no. of episodes per 10,000 patient-days (range).
b versus ICUs in university hospitals.P ! .01
c versus ICUs in all hospitals.Pp .11
d Includes oncohematology units.
e versus medical wards in university-affiliated hospitals.P ! .05
f versus medical ICUs in university hospitals.P ! .01
g versus surgical ICUs in university hospitals.Pp .11
h versus medical ICUs in university-affiliated hospitals.Pp .14
i Includes neonatal ICUs.
j Hospital location of 2 patients is unknown.
k versus university-affiliated hospitals.Pp .17
l Hospital location of 4 patients is unknown.
days per year (range, 0.38–0.58 episodes per 10,000 patient-
days per year). No significant trend was observed during the
10-year period among university hospitals and university-
affiliated hospitals (figure 1C). It is notable, however, that the
annual incidence of candidemia in university-affiliated hospi-
tals increased significantly, from 0.23 to 0.56 episodes per
10,000 patient-days ( ; ), during 1991–1996.rp 0.93 P ! .05
Candida species distribution during 1991–2000. Data on
1137 candidemia episodes were available for the period 1991–
2000 from all participating hospitals. Overall, the species dis-
tribution was stable (figure 3). C. albicans remained the pre-
dominant species, ranging between 64% and 68% of all isolates
recovered, and C. glabrata was the second most common spe-
cies recovered (14% during 1991–1993 and 15% during 2000).
C. tropicalis emerged as the third most common pathogen (2%
during 1991–1993 and 9% during 2000; ), whereas theP ! .005
incidence of C. parapsilosis decreased (6% during 1991–1993
and 1% during 2000; ). C. krusei remained rare (2%P ! .05
during 1991–1993 and 2% during 2000). During the 10-year
study period, the overall proportion of non-albicans species of
Candida was 36% in university hospitals and 31% in university-
affiliated hospitals ( ). C. glabrata accounted for 15.5%Pp .18
and 10% of isolates, respectively ( ).P ! .05
Secular trends of the incidence of candidemia caused by
different Candida species were available from 3 university hos-
pitals and 3 university-affiliated hospitals (774 isolates; figure
4A). Although the annual incidence varied over time for C.
albicans (median, 0.34 episodes per 10,000 patient-days; range,
0.26–0.38 episodes per 10,000 patient-days), C. glabrata plus
C. krusei (median, 0.075 episodes per 10,000 patient-days;
range, 0.04–0.12 episodes per 10,000 patient-days), and other
non-albicans Candida species (median, 0.085 episodes per
10,000 patient-days; range, 0.04–0.13 episodes per 10,000
patient-days), no statistically significant trend was observed.
Similarly, no trend was observed when university and univer-
sity-affiliated hospitals were analyzed separately.
Fluconazole administration. The annual quantity of flu-
conazole administered in 1991–2000 in these 3 university and
3 university-affiliated hospitals is illustrated in figure 4B. A
progressive increase in the quantities of the parenteral and oral
forms that were administered was observed. In 1991, 2.1 and
5.2 g per 10,000 patient-days were administered intravenously
and orally, respectively; in 2000, 12.2 and 17.8 g per 10,000
patient-days were administered, respectively ( [rp 0.99 P !
] and [ ], respectively). Identical trends were.001 rp 0.97 P ! .001
observed when university and university-affiliated hospitals were
analyzed separately.
Antifungal susceptibility testing. In 1999–2000, data on
fluconazole susceptibility were available for 96 (39%) of 245
Candida isolates, comprising 90 (60%) of 151 isolates from
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Figure 2. Patient location in the hospital at time of candidemia in 3 university and 2 university-affiliated tertiary care institutions during 1991–
1995 and 1996–2000. The following differences or trends were observed in a comparison of both periods: pediatric wards, ; medical wards,P ! .01
; and medical ICUs, . Pediatric ICUs include neonatal ICUs.Pp .06 Pp .06
university hospitals and 6 (6%) of 94 from university-affiliated
hospitals ( ). Fifty-six C. albicans isolates and 40 non-P ! .001
albicans isolates of Candida were tested for susceptibility to
fluconazole, and 1 (2%) and 8 (20%) of the isolates, respec-
tively, were resistant, according to the NCCLS criteria. Resistant
non-albicans isolates of Candida included 5 C. glabrata isolates,
1 C. krusei isolate, 1 Candida norvegiensis isolate, and 1 C.
tropicalis isolate. During 1997–1998, a similar proportion of
fluconazole-resistant non-albicans isolates of Candida was re-
ported (5 [24%] of 21 isolates, of which 4 were C. glabrata and
1 was C. krusei), suggesting that the rate of azole resistance did
not increase during 1997–2000. No resistance to amphotericin
B and 5-flucytosine was observed in 1999–2000 in 35 and 29
Candida isolates, respectively. Because antifungal susceptibility
testing became common practice only during the late 1990s,
data on 10-year trends are not available.
DISCUSSION
We conducted a comprehensive analysis of trends of candi-
demia, hospital characteristics, activities at-risk for Candida
infections, and fluconazole use in Swiss tertiary care hospitals
during 1991–2000. Candida species ranked among the top 10
bloodstream pathogens that were recovered during the study
period, but no change in the incidence of candidemia occurred,
despite an increasing number of high-risk clinical settings. Al-
though fluconazole use increased significantly over the 10-year
period, no shift toward azole-resistant non-albicans species of
Candida and no resistance in C. albicans were observed.
Invasive candidiasis emerged as a major problem in US hos-
pitals in the 1980s [5, 7]. A similar evolution was observed in
Asia [18]. However, an inverse trend was observed during 1989–
1999 among ICUs in US hospitals reporting to the NNIS system
[8]. In Europe, contrasting data were reported in the early
1990s—the incidence of candidemia increased in The Neth-
erlands and remained stable in Norway [13, 15]. No significant
change was reported in 1 Swiss hospital between 1989 and 2000
[19]. Other recent multicenter longitudinal data from Europe
are lacking.
We studied the epidemiology of candidemia over a 10-year
period in all university hospitals and the majority of university-
affiliated tertiary care centers, serving 180% of the population
of Switzerland. The analysis of hospital characteristics and ac-
tivities shows a significant increase in the number of blood
cultures and transplantations performed, representing an in-
creased number of clinical settings at high risk for candidemia.
Candida organisms ranged from the sixth through ninth most
recovered bloodstream pathogens and accounted for 2%–3%
of all isolates during this period. These data are comparable to
those reported from other European countries. In contrast,
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Figure 3. Evolution of the distribution of Candida species in all surveyed hospitals during 1991–2000. The proportion of Candida tropicalis increased
from 2% to 9% ( ) and that of Candida parapsilosis decreased from 6% to 1% ( ). For the other Candida species, no significant changeP ! .005 P ! .05
was observed.
Candida species ranged from the fourth to fifth most recovered
bloodstream isolates and accounted for 7%–10% of all infec-
tions in the United States.
In Switzerland, the incidence of candidemia remained es-
sentially unchanged during the 10-year study period. In 2000,
0.54 episodes per 10,000 patient-days (0.36 episodes per 1000
hospital admissions) and 0.40 episodes per 10,000 patient-days
(0.15 episodes per 1000 hospital admissions) were reported in
university and university-affiliated hospitals, respectively. In
1989, the NNIS system described 2- to 3-fold higher rates—
0.61 and 0.37 episodes per 1000 discharges in large (1500-bed)
and small (!500-bed) US teaching hospitals, respectively [5].
Ten years later, Berrouane et al. [20] observed 0.98 episodes of
candidemia per 10,000 patient-days in 1 US tertiary care center.
The following incidence rates reported in European countries
in the 1990s were closer to those found in Switzerland: 0.72
episodes per 10,000 patient-days in Dutch university hospitals,
0.52 episodes per 10,000 patient-days (0.38 episodes per 1000
admissions) in French teaching hospitals, 0.44 episodes per
10,000 patient-days (0.38 episodes per 1000 admissions) in Ital-
ian hospitals, and 0.37 episodes per 10,000 patient-days in Nor-
wegian university hospitals [13, 15, 21, 22].
Critically ill and severely immunocompromised patients are
at particularly high risk for invasive candidiasis. In Switzerland,
one-third of all episodes of candidemia occurred in ICUs, one-
third in medical wards (including hemato-oncology units), and
one-fourth in surgical wards. These proportions are comparable
with those described in US hospitals [6, 20]. In 2000, we ob-
served a 7-fold higher incidence of candidemia in ICUs (2.36
episodes per 10,000 patient-days) than in wards (0.33 episodes
per 10,000 patient-days). In NNIS system hospitals, the inci-
dence of candidemia in ICUs dropped from 5 to 2 episodes
per 10,000 patient-days between 1991 and 1999 [8]. No com-
parative data in this clinical setting are available from other
European countries.
The distribution of Candida species plays a key role for es-
tablishing efficient management strategies [23, 24]. The emer-
gence of Candida species with decreased susceptibility or in-
trinsic resistance to azoles was a major concern in the 1990s.
This phenomenon was first reported in the United States in
neutropenic recipients of bone marrow transplants [9]. Other
North American and European investigators confirmed these
observations in larger hospital settings [10, 11, 13, 20, 22, 25,
26]. Trick et al. [8] recently confirmed these trends in patients
in US ICUs. In institutions where this shift occurred, propor-
tions of C. glabrata and C. krusei were 15%–45% and 5%–
20%, respectively. However, this phenomenon was not described
in other studies from Canada, Latin America, and Europe [15,
27]. In Switzerland, no shift to azole-resistant Candida spe-
cies was observed over a 10-year period. C. albicans remained
the predominant species, followed by C. glabrata; C. tropicalis
emerged as the third most common species, the frequency of C.
parapsilosis decreased, and C. krusei remained uncommon. The
species distributions were very close to those reported in Norway
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Figure 4. A, Incidence of candidemia due to different Candida species in 3 university and 3 university-affiliated hospitals during 1991–2000. No
statistically significant trend was observed. B, Use of fluconazole in 3 university and 3 university-affiliated hospitals during 1991–2000. A statistically
significant increase was found for the intravenous ( ; ) and oral form ( ; ).rp 0.99 P ! .001 rp 0.97 P ! .001
during the early 1990s, in Italy during an ECCM survey con-
ducted in the late 1990s, and in Wales [15, 22, 28].
The role of the widespread use of azoles in the shift to re-
sistant Candida species has been largely debated and remains
controversial [12]. Two groups observed an important increase
of C. glabrata fungemia in the 1990s and analyzed fluconazole
consumption over time. Voss et al. [13] evaluated the annual
nationwide fluconazole use in The Netherlands in kilograms
and observed a 4-fold increase between 1990 and 1995. Sim-
ilarly, Berrouane et al. [20] observed a substantial increase in
fluconazole use, from 3 to 33 g per 10,000 patient-days in 1990
and 1994, respectively. In contrast, a study from 1 Swiss uni-
versity hospital reported no shift to non-albicans species of
Candida, despite a significant increase in fluconazole use be-
tween 1989 and 2000 [19]. In the current study, the use of
fluconazole in 6 university and university-affiliated hospitals
increased 4-fold, from 7.3 to 30 g per 10,000 patient-days in
1991 and 2000, respectively. The association between the pro-
gressive rise in fluconazole use and the constant incidence of
candidemia suggests that prophylactic and preemptive and/or
empirical strategies in high-risk clinical settings might have
played a role in stabilizing the incidence of the disease [29–
31]. On the other hand, improved infection-control practices
might have contributed to such stabilization, despite an increase
of high-risk patient-care activities. The increased use of flu-
conazole did not influence the distribution of the different
Candida species during the 10-year period under study.
Despite the lack of a centralized laboratory, this retrospective
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study represents the largest European series of candidemia and
one of the largest worldwide. It provides a longitudinal overview
of the secular trends associated with patient-care activities,
which is representative of the entire country over a 10-year
period. The incidence of candidemia remained stable, despite
increasing high-risk activities, and no shift to azole-resistant
Candida species was observed. However, a prospective survey
is needed to detect the possible emergence of resistance associ-
ated with a sustained use of azole antifungals.
FUNGAL INFECTION NETWORK
OF SWITZERLAND
Participating hospitals and affiliated microbiology laboratories
of the Fungal Infection Network of Switzerland (responsible
infectious disease specialist(s); responsible clinical microbiol-
ogist): Kantonsspital, Aarau (T. Bregenzer; I. Heinzer); Kan-
tonsspital, Basel (U. Fluckiger; R. Frei); Universita¨tskinderspi-
tal, Basel (U. Heininger; R. Hertel); Inselspital, Bern (M.
Ta¨uber; K. Mu¨hlethaler); Kantonsspital, Chur (F. Fleisch; K.
Eschmann); Hoˆpital Cantonal, Fribourg (C. Chuard; D. Frach-
eboud); Hoˆpitaux Universitaires, Gene`ve (P. Eggimann, J.
Garbino, and D. Pittet; P. Rohner); Hoˆpital Communal, La-
Chaux-de-Fonds (D. Genne´; R. Lienhard); Centre Hospitalier
Universitaire Vaudois, Lausanne (T. Calandra, M.P. Glauser,
and O. Marchetti; J. Bille); Kantonsspital, Liestal (W. Zimmerli;
S. Graf); Ospedale Civico, Lugano (E. Bernasconi; M. Dolina);
Kantonsspital, Luzern (M. Rossi; T. Rutz); Hoˆpital des Cadolles,
Neuchaˆtel (R. Malinverni; R. Lienhard); Kantonsspital, St. Gal-
len (K. Boggian; D. Buhl); Universita¨tsspital, Zu¨rich (C. Ruef;
G. Scha¨r); Universita¨tskinderspital, Zu¨rich (D. Nadal and C.
Berger [infectious diseases specialists]); Stadtspital Triemli, Zu¨r-
ich (J. Gubler [infectious diseases specialist]).
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